This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David S. Dahl, MD; Paul Schraeder, MD; Merle Evenson, PhD; Stanley Goldfarb, MD; Henry A. Peters, MD
Madison, Wis

Arch Neurol. 1973;29(6):449-450.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor..—

A fortuitous reevaluation of the patient in question (Arch Neurol 27:456-457, 1972) enabled us to provide additional confirmation that penicillamine can cause polymyositis, and to reply to Dr. Scheinberg's comments.

In October 1972, when the patient's levels of creatine phosphokinase (CPK) and serum glutamic (SGOT) and pyruvic (SGPT) transaminases were within normal limits, penicillamine therapy, 1 gm/day, was reinstituted. By December 1972, she again noted proximal muscle weakness and immediately discontinued taking the penicillamine. During a clinic visit in January 1973, her CPK value was 916 Karmen units (normal, less than 120 Karmen units). By March 1973, she was clearly worse and complained of mild dysphagia. Her CPK level peaked at 6,910 Karmen units and she was admitted to the hospital for reevaluation. Examination showed mild but definite proximal weakness in all limbs and also in the sternocleidomastoid muscles. She felt, however, that she was improving spontaneously. Her . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?